Clive Dix: Last News

The use of the Oxford/AstraZeneca Covid-19 vaccine in vulnerable people may be resulting in a lower death toll in the UK compared to Europe, according to the former chief of the country's vaccine taskforce.

Covid jab by September - or sooner.Every adult could receive both doses by August or September, the chief of the vaccine taskforce has said.The UK has given 15.6million people a first dose and 546,165 a second, which is the fastest roll-out per capita of any large country, the Mirror reports.Clive Dix, told Sky News on Tuesday: "We're probably talking August time or September time all done, maybe sooner if we need to."He said the UK is "definitely" in a position to receive the promised supply of vaccines over the next few months to meet target.He added: "We are confident within the vaccine taskforce now that the supply we're going to get will take to us to a position where we can vaccinate as many people as the UK wants to vaccinate."The UK

direct to your inboxEvery adult in the UK could receive the required two doses of a coronavirus vaccine by September, or 'maybe sooner', health bosses said tonight.Dr Clive Dix, chairman of the UK Vaccines Taskforce, said he was confident secure supply chains meant 'we can vaccinate as many people as the UK wants to vaccinate'.He said it could be 'August time or September time all done, maybe sooner if we need to'.The vaccine tsar's comments come as the Government today confirmed the number of people who have received their first dose of a vaccine is now approaching 15.6 million.Figures show 546,165 have been vaccinated with a second dose.Downing Street has previously confirmed the vaccine programme intends to reach all those aged 50 and

Health officials say the coronavirus jab rollout is on track for every adult in the UK to have had two doses by September.

direct to your inboxA new vaccine against Covid-19 has over 89% efficacy, trial results have shown.UK phase three trials of the Novavax Covid-19 vaccine have found it demonstrated 89.3% efficacy against the virus.Preliminary analysis has also showed the new UK variant was detected in more than half of the Covid-19 cases recorded in the trials, with the vaccine candidate shown to be 95.6% effective against the original strain and 85.6% effective against the variant.The study involved more than 15,000 participants aged 18 to 84, with 27% aged over 65.Clive Dix, chairman of the UK Vaccine Taskforce, said: “These are spectacular results, and we are very pleased to have helped Novavax with the development of this vaccine.